SOUL Trial: Oral Semaglutide and MACE Reduction Cardiovascular protection from an oral GLP-1 in high-risk type 2 diabetes. (2026). Diabzen, 4(19), 38-39. https://thediabzen.com/index.php/d/article/view/62